Welcome to BioSeeker Group!

The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others

Additional Information

Published Date Sep 27, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1944
PDF Fact Sheet View Fact Sheet for the report The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others.

    To find out more about The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the antibody drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of antibody drugs in cancer is split between the 34% which have unique drug target strategies and the other part (66%) which have head-to-head target competing antibody drugs in 76 different clusters. The latter has a competing ratio which is two times higher than the comparable average of the antibody drugs in general. Contributing to this fact is heavily utilized drug target strategies like: MS4A1, ERBB2 and EGFR.

* Eight out of ten drug target strategies in Phase II development are new to antibody drugs in cancer and the greatest numbers of new target strategies are found in Preclinical (30%) and Phase II development (21%).

* The highest number of described target strategies among antibody drugs are found in Colorectal Cancer, Ovarian Cancer and Prostate Cancer. Antibody drugs are experiencing targeting competition in five out of every nine cancer indications described, and more so in Breast Cancer, Colorectal Cancer and non-Hodgkin’s Lymphoma. Here, Ewing’s Sarcoma makes out its own class by having five drugs but only towards one target strategy.

* The highest number of described drug target strategies of antibody drugs belongs to Hoffmann-La Roche, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Immunomedics. However, when looking at the total number of drugs the order of the companies shifts into Hoffmann-La Roche, Immunomedics, Bristol-Myers Squibb, AstraZeneca and Eli Lilly.

* From an indication perspective it is Hoffmann-La Roche, Eli Lilly, Amgen, Pfizer and Bristol-Myers Squibb which take the lead in the widest coverage of cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any antibody drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 23
4.2 List of Tables 23
5 Introduction 35
5.1 The Scope of this Report 35
5.2 Definitions 38
5.3 Abbreviations 38
6 Consider the Therapeutic Target Among Antibody Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment 39
6.1 Drug Repositioning in Oncology 39
6.2 Introduction to Targets of Antibody Drugs in Oncology 40
6.2.1 Antigen Binding Targets 49
6.2.2 Auxiliary Transport Protein Activity Targets 51
6.2.3 B Cell Receptor Activity Targets 53
6.2.4 Carboxypeptidase Activity Targets 54
6.2.5 Catalytic Activity Targets 56
6.2.6 Cell Adhesion Molecule Activity Targets 60
6.2.7 Chaperone Activity Targets 86
6.2.8 Chemokine Activity Targets 90
6.2.9 Cofactor Binding Targets 95
6.2.10 Complement Activity Targets 97
6.2.11 Cysteine-type Peptidase Activity Targets 101
6.2.12 Cytokine Activity Targets 103
6.2.13 Defense/Immunity Protein Activity Targets 112
6.2.14 DNA Topoisomerase Activity Targets 113
6.2.15 Extracellular Ligand-gated Ion Channel Activity Targets 116
6.2.16 Extracellular Matrix Structural Constituent Targets 117
6.2.17 G-protein Coupled Receptor Activity Targets 123
6.2.18 Growth Factor Activity Targets 130
6.2.19 Hormone Activity Targets 144
6.2.20 Hydrolase Activity Targets 145
6.2.21 Intracellular Ligand-gated Ion Channel Activity Targets 147
6.2.22 Isomerase Activity Targets 148
6.2.23 Kinase Binding Targets 149
6.2.24 Metallopeptidase Activity Targets 150
6.2.25 MHC Class I Receptor Activity Targets 154
6.2.26 Molecular Function Unknown Targets 156
6.2.27 Oxidoreductase Activity Targets 187
6.2.28 Peptidase Activity Targets 188
6.2.29 Peptide Hormone Targets 191
6.2.30 Protease Inhibitor Activity Targets 193
6.2.31 Protein Binding Targets 195
6.2.32 Protein Serine/Threonine Kinase Activity Targets 196
6.2.33 Receptor Activity Targets 200
6.2.34 Receptor Binding Targets 272
6.2.35 Receptor Signaling Complex Scaffold Activity Targets 286
6.2.36 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 288
6.2.37 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets 289
6.2.38 RNA-directed DNA Polymerase Activity Targets 290
6.2.39 Serine-type Peptidase Activity Targets 291
6.2.40 Structural Constituent of Cytoskeleton Targets 294
6.2.41 Structural Molecule Activity Targets 296
6.2.42 T Cell Receptor Activity Targets 297
6.2.43 Transcription Factor Activity Targets 300
6.2.44 Transcription Regulator Activity Targets 307
6.2.45 Translation Regulator Activity Targets 310
6.2.46 Transmembrane Receptor Activity Targets 311
6.2.47 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 321
6.2.48 Transporter Activity Targets 362
6.2.49 Unclassified Targets 366
6.2.50 Other Targets 367
6.3 The Cancer Genome Project and Targets of Antibody Drugs in Oncology 369
6.3.1 Targets of Antibody Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 369
6.4 Antibody Therapeutics is Stimulated by Available Structure Data on Biological Targets 376
6.5 Target-Target Interactions among Identified Targets of Antibody Drugs in Oncology 380
6.6 The Drug-Target Competitive Landscape 384
6.7 Protein Expression Levels of Identified Targets of Antibody Drugs in Oncology 389
6.8 Pathway Assessment of Antibody Drugs in Oncology 392
6.8.1 Tools for Analysis of Cancer Pathways 393
6.8.2 Pathway Assessment 394
7 Emerging New Products to Established Ones: Drug Target Strategies of Antibody Drugs in Oncology by their Highest Stage of Development 431
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Antibody Drugs in Oncology 435
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Oncology 437
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Oncology 439
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Oncology 444
7.5 Preclinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Oncology 449
7.6 Drug Target Strategies of Suspended or Terminated Antibody Drugs in Oncology 458
7.7 Target Strategy Development Profiles of Antibody Drugs in Oncology 463
7.7.1 Marketed 469
7.7.2 Pre-registration 488
7.7.3 Phase III 490
7.7.4 Phase II 505
7.7.5 Phase I 569
7.7.6 Preclinical 612
7.7.7 Suspended 693
7.7.8 Ceased 694
7.8 The Competition Through Close Mechanistic Approximation of Antibody Drugs in Oncology 761
8 Selecting Subindication for Antibody Drugs in Oncology 769
8.1 Acute Lymphocytic Leukemia 772
8.2 Acute Myelogenous Leukemia 774
8.3 B-cell Lymphoma 776
8.4 Basal Cell Cancer 778
8.5 Biliary Cancer 779
8.6 Bladder Cancer 780
8.7 Bone Cancer 782
8.8 Brain Cancer 784
8.9 Breast Cancer 786
8.10 Cancer (general) 790
8.11 Cancer Diagnosis 791
8.12 Cancer Fatigue 793
8.13 Carcinoid 794
8.14 Cervical Cancer 795
8.15 Chronic Lymphocytic Leukemia 796
8.16 Chronic Myelogenous Leukemia 799
8.17 Chronic Myelomonocytic Leukemia 800
8.18 CNS Cancer 801
8.19 Colorectal Cancer 802
8.20 Endometrial Cancer 806
8.21 Ewing’s Sarcoma 807
8.22 Fallopian Tube Cancer 808
8.23 Gastrointestinal Cancer (general) 809
8.24 Gastrointestinal Stomach Cancer 810
8.25 Gastrointestinal Stromal Cancer 812
8.26 Genitourinary Cancer 813
8.27 Hairy Cell Leukemia 814
8.28 Head and Neck Cancer 815
8.29 Hematological Cancer (general) 817
8.30 Hodgkin’s Lymphoma 818
8.31 Leiomyo Sarcoma 820
8.32 Leukemia (general) 821
8.33 Liver Cancer 823
8.34 Lung Cancer (general) 825
8.35 Lymphoma (general) 827
8.36 Malignant ascites 828
8.37 Melanoma 829
8.38 Merkel Cell Carcinoma 831
8.39 Mesothelioma 832
8.40 Myelodysplastic Syndrome 833
8.41 Myeloma 834
8.42 Nasopharyngeal Cancer 837
8.43 Neuroblastoma 838
8.44 Neuroectodermal Sarcoma 839
8.45 Neuroendocrine Cancer (general) 840
8.46 non-Hodgkin’s Lymphoma 841
8.47 Non-Small Cell Lung Cancer 845
8.48 Oesophageal Cancer 848
8.49 Oral Cancer 850
8.50 Osteo Sarcoma 851
8.51 Ovarian Cancer 852
8.52 Pancreatic Cancer 855
8.53 Peritoneal Cancer 858
8.54 Pituitary Adenoma 860
8.55 Prostate Cancer 861
8.56 Radio/chemotherapy-induced Anemia 864
8.57 Radio/chemotherapy-induced Bone Marrow Injury (general) 865
8.58 Radio/chemotherapy-induced Mucositis 866
8.59 Radio/chemotherapy-induced Thrombocytopenia 867
8.60 Renal Cancer 868
8.61 Rhabdomyo Sarcoma 870
8.62 Sarcoma (general) 871
8.63 Skin Cancer (general) 872
8.64 Small Cell Lung Cancer 873
8.65 Soft Tissue Sarcoma 875
8.66 Solid Tumor 876
8.67 Squamous Cell Cancer 879
8.68 Synovial Sarcoma 880
8.69 T-cell Lymphoma 881
8.70 Testicular Cancer 882
8.71 Thymoma Cancer 883
8.72 Thyroid Cancer 884
8.73 Unspecified Cancer Indication 885
8.74 Vaccine adjunct 892
8.75 Waldenstrom`s hypergammaglobulinemia 893
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Antibody Drug Pipeline in Oncology by Investigator 894
9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 898
9.2 Competitive Fall-Out Assessment 900
9.3 A&G Pharmaceutical 902
9.4 Abbott 905
9.5 Abiogen 912
9.6 Ablynx 919
9.7 AC Immune 923
9.8 Acceleron Pharma 926
9.9 Access 929
9.10 Actinium Pharmaceuticals 934
9.11 Active Biotech 938
9.12 Adherex 942
9.13 Affibody 945
9.14 Affimed Therapeutics 950
9.15 Affitech 958
9.16 AGY Therapeutics 964
9.17 Aida Pharmaceuticals 967
9.18 Alder Biopharmaceuticals 971
9.19 Alethia Biotherapeutics 976
9.20 Alexion 979
9.21 Alfacell 983
9.22 Algeta 986
9.23 ALSP 991
9.24 Altor BioScience 996
9.25 Amgen 999
9.26 Amorfix Life Sciences 1012
9.27 Antisoma 1016
9.28 Aphios 1022
9.29 Apricus Biosciences 1026
9.30 Arana Therapeutics 1032
9.31 Arca biopharma 1035
9.32 arGEN-X 1039
9.33 Astellas 1043
9.34 AstraZeneca 1047
9.35 Avaxia 1062
9.36 AVEO 1066
9.37 Bayer 1074
9.38 Berkeley Lab 1078
9.39 Biocon 1081
9.40 Biogen Idec 1084
9.41 BioInvent 1097
9.42 Biolex 1101
9.43 BioLineRx 1105
9.44 Biosceptre 1108
9.45 Biotecnol 1111
9.46 Biotest 1117
9.47 Boehringer Ingelheim 1120
9.48 Bristol-Myers Squibb 1123
9.49 BTG 1141
9.50 Cancer Innovations 1145
9.51 Cancer Research Technology 1148
9.52 Celldex Therapeutics 1162
9.53 Celltrion 1169
9.54 Celtic Pharma 1176
9.55 Center of Molecular Immunology 1180
9.56 CG Therapeutics 1186
9.57 Circadian Technologies 1189
9.58 CSL 1193
9.59 CuraGen 1196
9.60 CureTech 1199
9.61 CytImmune Sciences 1203
9.62 Daiichi Sankyo 1206
9.63 Dendreon 1211
9.64 DiaMedica 1216
9.65 Dompe 1219
9.66 Dr Reddy’s 1223
9.67 Dyax 1228
9.68 Eisai 1232
9.69 Elan 1238
9.70 Eli Lilly 1241
9.71 Emergent BioSolutions 1259
9.72 Epitomics 1262
9.73 EUSA Pharma 1268
9.74 Faron Pharmaceuticals 1271
9.75 Favrille 1274
9.76 Femta Pharmaceuticals 1279
9.77 FibroGen 1283
9.78 Five Prime Therapeutics 1286
9.79 Fusion Antibodies 1289
9.80 Galaxy Biotech 1292
9.81 GammaCan 1295
9.82 Ganymed Pharmaceuticals 1299
9.83 Gene Techno Science 1302
9.84 Genencor 1305
9.85 Genentech 1308
9.86 Genmab 1316
9.87 Genomic Systems 1330
9.88 GenPat77 1333
9.89 Gilead Sciences 1336
9.90 GlaxoSmithKline 1339
9.91 Gliknik 1345
9.92 Glycotope 1352
9.93 Green Cross 1359
9.94 Hawthorn Pharmaceuticals 1364
9.95 Hoffmann-La Roche 1367
9.96 Human Genome Sciences 1402
9.97 IDM Pharma 1407
9.98 ImClone Systems 1414
9.99 IMED 1419
9.100 Immune Pharmaceuticals 1422
9.101 ImmunoCellular Therapeutics 1425
9.102 ImmunoGen 1428
9.103 Immunomedics 1441
9.104 Immutep 1466
9.105 Innate Pharma 1469
9.106 InNexus Biotechnology 1474
9.107 Intracel 1485
9.108 ISA Pharmaceuticals 1489
9.109 ISU ABXIS 1493
9.110 Johnson & Johnson 1498
9.111 Kaketsuken 1505
9.112 KaloBios 1508
9.113 Kirin Pharma 1511
9.114 Kissei 1516
9.115 Kyowa Hakko Kirin 1521
9.116 Kyto Biopharma 1525
9.117 LFB Biotechnologies 1528
9.118 LG Life Sciences 1536
9.119 MacroGenics 1541
9.120 MAT Biopharma 1547
9.121 Medarex 1552
9.122 MediGene 1557
9.123 MedImmune 1561
9.124 Menarini 1565
9.125 Merck & Co 1569
9.126 Merck KGaA 1574
9.127 Merrimack 1583
9.128 Micromet 1587
9.129 Mitsubishi Tanabe Pharma 1601
9.130 Mycenax 1604
9.131 Neovacs 1607
9.132 Neuren 1611
9.133 NIH – The US National Institute of Health 1614
9.134 NKT Therapeutics 1618
9.135 Non-industrial Sources 1621
9.136 Northwest Biotherapeutics 1627
9.137 Novartis 1630
9.138 OncoMed 1638
9.139 Oncothyreon 1642
9.140 Onyvax 1646
9.141 Oxford BioMedica 1649
9.142 Paladin Labs 1652
9.143 Panacea 1658
9.144 PanGenetics 1663
9.145 Patrys 1667
9.146 Pepscan Therapeutics 1672
9.147 Peregrine Pharmaceuticals 1676
9.148 Perseus Proteomics 1681
9.149 Pfizer 1684
9.150 Philogen 1699
9.151 Pierre Fabre 1703
9.152 Prima Biomed 1711
9.153 ProCell Therapeutics 1714
9.154 Prochon Biotech 1717
9.155 Progenics Pharmaceuticals 1721
9.156 Ramot 1724
9.157 Recepta biopharma 1727
9.158 Receptor BioLogix 1730
9.159 Regeneron 1734
9.160 Sanofi-Aventis 1741
9.161 SBI Biotech 1747
9.162 Scancell 1750
9.163 Seattle Genetics 1753
9.164 Shenogen 1760
9.165 Stainwei Biotech 1763
9.166 Sunol Molecular 1766
9.167 SuppreMol 1769
9.168 Switch Pharma 1772
9.169 Symphogen 1775
9.170 Synageva BioPharma 1780
9.171 SynerGene Therapeutics 1788
9.172 Takeda 1791
9.173 Targa Therapeutics 1794
9.174 TeGenero 1800
9.175 Teva 1803
9.176 Therapure Biopharma 1808
9.177 ThromboGenics 1811
9.178 Titan Pharmaceuticals 1816
9.179 Tolerx 1821
9.180 Tracon Pharmaceuticals 1825
9.181 Transgene 1828
9.182 Trillium Therapeutics 1831
9.183 Trion Pharma 1834
9.184 UCB 1841
9.185 United Therapeutics 1846
9.186 Vaccinex 1849
9.187 VasGene Therapeutics 1857
9.188 Viragen 1860
9.189 Viventia Biotech 1864
9.190 Wakunaga 1867
9.191 Wilex 1871
9.192 XBiotech 1874
9.193 Xencor 1878
9.194 Xerion 1893
9.195 Xoma 1898
9.196 Y’s Therapeutics 1902
9.197 YM BioSciences 1906
9.198 Zenotech 1911
10 Disclaimer 1917
11 Drug Index 1918
12 Company Index 1934

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Antibody Drugs in Oncology 383
Figure 2: The Drug-Target Competitive Landscape of Antibody Drugs in Oncology - Large Clusters 385
Figure 3: The Drug-Target Competitive Landscape Antibody Drugs in Oncology - Smaller Clusters 386
Figure 4: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Oncology - Larger Clusters 387
Figure 5: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Oncology - Smaller Clusters 388

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Antibody Drug Pipeline in Oncology by Stage of Development 35
Table 3: Head to Head Target Competition among Antibody Drugs in Oncology 35
Table 4: Overview of Drug Target Strategy Themes 40
Table 5: Terminally Ceased Targets of Antibody Drugs in Oncology 41
Table 6: Official Gene Name to Target Profle 42
Table 7: Targets of Antibody Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 370
Table 8: Identity of Drug Targets with Available Biological Structures 376
Table 9: Number of Target-Target Interactions among Targets of Antibody Drugs in Oncology 381
Table 10: Available Protein Expression Profiles of Antibody Drug Targets in Oncology 389
Table 11: Pathway Summary 394
Table 12: Drug Targets without any Identified Assigned Pathways 394
Table 13: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology 397
Table 14: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology 411
Table 15: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology 427
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 431
Table 17: Top Competitive Target Strategies of Antibody Drugs in Oncology 432
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Antibody Drugs in Oncology 435
Table 19: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Oncology being Marketed or in Pre-registration 436
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Antibody Drugs in Oncology 437
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Oncology 438
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Antibody Drugs in Oncology 439
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Oncology 442
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Antibody Drugs in Oncology 444
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Oncology 448
Table 26: New and Unique Target Strategies in Preclinical Development of Antibody Drugs in Oncology 449
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Oncology 454
Table 28: Target Strategies of Suspended and Terminated Antibody Drugs in Oncology 458
Table 29: Connecting Target Strategy with Its Profile Identification Number 463
Table 30: The Competition Through Close Mechanistic Approximation Among Antibody Drugs in Oncology 761
Table 31 Competitive Summary by Cancer Indication of Antibody Drugs 770
Table 32: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia 772
Table 33: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 773
Table 34: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia 774
Table 35: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 775
Table 36: Target Strategy Development Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma 776
Table 37: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 777
Table 38: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer 778
Table 39: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Biliary Cancer 779
Table 40: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs 779
Table 41: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bladder Cancer 780
Table 42: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 781
Table 43: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bone Cancer 782
Table 44: The Competition through Close Mechanistic Approximation between Bone Cancer Drugs 783
Table 45: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Brain Cancer 784
Table 46: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 785
Table 47: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Breast Cancer 786
Table 48: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 788
Table 49: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer (general) 790
Table 50: Target Strategy Development Profiles of Antibody Compounds for Cancer Diagnosis 791
Table 51: The Competition through Close Mechanistic Approximation between Cancer Diagnosis Compounds 792
Table 52: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer Fatigue 793
Table 53: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Carcinoid 794
Table 54: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cervical Cancer 795
Table 55: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 795
Table 56: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia 796
Table 57: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 797
Table 58: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia 799
Table 59: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 799
Table 60: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelomonocytic Leukemia 800
Table 61: Target Strategy Development Profiles of Antibody Drugs for the Treatment of CNS Cancer 801
Table 62: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Colorectal Cancer 802
Table 63: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 804
Table 64: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Endometrial Cancer 806
Table 65: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ewing’s Sarcoma 807
Table 66: The Competition through Close Mechanistic Approximation between Ewing’s Sarcoma Drugs 807
Table 67: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer 808
Table 68: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general) 809
Table 69: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 809
Table 70: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer 810
Table 71: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 811
Table 72: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer 812
Table 73: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer 813
Table 74: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs 813
Table 75: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia 814
Table 76: The Competition through Close Mechanistic Approximation between Hairy Cell Leukemia Drugs 814
Table 77: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer 815
Table 78: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 816
Table 79: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general) 817
Table 80: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hodgkin’s Lymphoma 818
Table 81: The Competition through Close Mechanistic Approximation between Hodgkin’s Lymphoma Drugs 819
Table 82: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma 820
Table 83: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leukemia (general) 821
Table 84: The Competition through Close Mechanistic Approximation between Leukemia (general) Drugs 822
Table 85: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Liver Cancer 823
Table 86: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 824
Table 87: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lung Cancer (general) 825
Table 88: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 826
Table 89: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lymphoma (general) 827
Table 90: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Malignant Ascites 828
Table 91: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Melanoma 829
Table 92: The Competition through Close Mechanistic Approximation between Melanoma Drugs 830
Table 93: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Merkel Cell Carcinoma 831
Table 94: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Mesothelioma 832
Table 95: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myelodysplastic Syndrome 833
Table 96: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 833
Table 97: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myeloma 834
Table 98: The Competition through Close Mechanistic Approximation between Myeloma Drugs 836
Table 99: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Nasopharyngeal Cancer 837
Table 100: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroblastoma 838
Table 101: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroectodermal Sarcoma 839
Table 102: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroendocrine Cancer (general) 840
Table 103: Target Strategy Development Profiles of Antibody Drugs for the Treatment of non-Hodgkin’s Lymphoma 841
Table 104: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs 843
Table 105: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Non-Small Cell Lung Cancer 845
Table 106: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 847
Table 107: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oesophageal Cancer 848
Table 108: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 849
Table 109: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oral Cancer 850
Table 110: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Osteo Sarcoma 851
Table 111: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs 851
Table 112: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ovarian Cancer 852
Table 113: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 854
Table 114: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pancreatic Cancer 855
Table 115: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 857
Table 116: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Peritoneal Cancer 858
Table 117: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 859
Table 118: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pituitary Adenoma 860
Table 119: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Prostate Cancer 861
Table 120: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 863
Table 121: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Anemia 864
Table 122: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 865
Table 123: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Mucositis 866
Table 124: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Thrombocytopenia 867
Table 125: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Renal Cancer 868
Table 126: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 869
Table 127: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Rhabdomyo Sarcoma 870
Table 128: The Competition through Close Mechanistic Approximation between Rhabdomyo Sarcoma Drugs 870
Table 129: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Sarcoma (general) 871
Table 130: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Skin Cancer (general) 872
Table 131: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Small Cell Lung Cancer 873
Table 132: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 874
Table 133: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Soft Tissue Sarcoma 875
Table 134: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Solid Tumor 876
Table 135: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 878
Table 136: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Squamous Cell Cancer 879
Table 137: The Competition through Close Mechanistic Approximation between Squamous Cell Cancer Drugs 879
Table 138: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Synovial Sarcoma 880
Table 139: Target Strategy Development Profiles of Antibody Drugs for the Treatment of T-cell Lymphoma 881
Table 140: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Testicular Cancer 882
Table 141: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thymoma Cancer 883
Table 142: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thyroid Cancer 884
Table 143: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 884
Table 144: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Unspecified Cancer Indication 885
Table 145: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 889
Table 146: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Vaccine adjunct 892
Table 147: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Waldenstrom`s hypergammaglobulinemia 893
Table 148: The Competition through Close Mechanistic Approximation between Waldenstrom`s hypergammaglobulinemia Drugs 893
Table 149: Competitive Summary by Investigator of Antibody Drug Development 894
Table 150: Summary Table of Corporate Changes in the Competitive Landscape of Antibody Drug Development in Oncology 898
Table 151: Example of a Competitive Fall-Out Table (Targeting ERBB2/Modified) 900
Table 152: A&G Pharmaceutical’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 902
Table 153: Abbott’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 905
Table 154: Abiogen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 912
Table 155: Ablynx’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 919
Table 156: AC Immune’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 923
Table 157: Acceleron Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 926
Table 158: Access’Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 929
Table 159: Actinium Pharmaceuticals’Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 934
Table 160: Active Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 938
Table 161: Adherex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 942
Table 162: Affibody’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 945
Table 163: Affimed Therapeutics’Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 950
Table 164: Affitech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 958
Table 165: AGY Therapeutics’Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 964
Table 166: Aida Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 967
Table 167: Alder Biopharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 971
Table 168: Alethia Biotherapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 976
Table 169: Alexion’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 979
Table 170: Alfacell’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 983
Table 171: Algeta’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 986
Table 172: ALSP’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 991
Table 173: Altor BioScience’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 996
Table 174: Amgen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 999
Table 175: Amorfix Life Sciences’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1012
Table 176: Antisoma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1016
Table 177: Aphios’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1022
Table 178: Apricus Biosciences’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1026
Table 179: Arana Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1032
Table 180: Arca biopharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1035
Table 181: arGEN-X’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1039
Table 182: Astellas’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1043
Table 183: AstraZeneca’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1047
Table 184: Avaxia’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1062
Table 185: AVEO’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1066
Table 186: Bayer’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1074
Table 187: Berkeley Lab’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1078
Table 188: Biocon’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1081
Table 189: Biogen Idec’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1084
Table 190: BioInvent’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1097
Table 191: Biolex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1101
Table 192: BioLineRx’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1105
Table 193: Biosceptre’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1108
Table 194: Biotecnol’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1111
Table 195: Biotest’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1117
Table 196: Boehringer Ingelheim’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1120
Table 197: Bristol-Myers Squibb’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1123
Table 198: BTG’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1141
Table 199: Cancer Innovations’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1145
Table 200: Cancer Research Technology’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1148
Table 201: Celldex Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1162
Table 202: Celltrion’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1169
Table 203: Celtic Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1176
Table 204: Center of Molecular Immunology’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1180
Table 205: CG Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1186
Table 206: Circadian Technologies’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1189
Table 207: CSL’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1193
Table 208: CuraGen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1196
Table 209: CureTech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1199
Table 210: CytImmune Sciences’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1203
Table 211: Daiichi Sankyo’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1206
Table 212: Dendreon’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1211
Table 213: DiaMedica’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1216
Table 214: Dompe’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1219
Table 215: Dr Reddy’s’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1223
Table 216: Dyax’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1228
Table 217: Eisai’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1232
Table 218: Elan’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1238
Table 219: Eli Lilly’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1241
Table 220: Emergent BioSolutions’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1259
Table 221: Epitomics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1262
Table 222: EUSA Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1268
Table 223: Faron Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1271
Table 224: Favrille’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1274
Table 225: Femta Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1279
Table 226: FibroGen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1283
Table 227: Five Prime Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1286
Table 228: Fusion Antibodies’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1289
Table 229: Galaxy Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1292
Table 230: GammaCan’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1295
Table 231: Ganymed Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1299
Table 232: Gene Techno Science’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1302
Table 233: Genencor’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1305
Table 234: Genentech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1308
Table 235: Genmab’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1316
Table 236: Genomic Systems’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1330
Table 237: GenPat77’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1333
Table 238: Gilead Sciences’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1336
Table 239: GlaxoSmithKline’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1339
Table 240: Gliknik’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1345
Table 241: Glycotope’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1352
Table 242: Green Cross’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1359
Table 243: Hawthorn Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1364
Table 244: Hoffmann-La Roche’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1367
Table 245: Human Genome Sciences’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1402
Table 246: IDM Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1407
Table 247: ImClone Systems’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1414
Table 248: IMED’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1419
Table 249: Immune Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1422
Table 250: ImmunoCellular Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1425
Table 251: ImmunoGen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1428
Table 252: Immunomedics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1441
Table 253: Immutep’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1466
Table 254: Innate Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1469
Table 255: InNexus Biotechnology’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1474
Table 256: Intracel’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1485
Table 257: ISA Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1489
Table 258: ISU ABXIS’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1493
Table 259: Johnson & Johnson’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1498
Table 260: Kaketsuken’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1505
Table 261: KaloBios’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1508
Table 262: Kirin Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1511
Table 263: Kissei’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1516
Table 264: Kyowa Hakko Kirin’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1521
Table 265: Kyto Biopharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1525
Table 266: LFB Biotechnologies’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1528
Table 267: LG Life Sciences’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1536
Table 268: MacroGenics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1541
Table 269: MAT Biopharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1547
Table 270: Medarex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1552
Table 271: MediGene’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1557
Table 272: MedImmune’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1561
Table 273: Menarini’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1565
Table 274: Merck & Co’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1569
Table 275: Merck KGaA’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1574
Table 276: Merrimack’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1583
Table 277: Micromet’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1587
Table 278: Mitsubishi Tanabe Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1601
Table 279: Mycenax’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1604
Table 280: Neovacs’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1607
Table 281: Neuren’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1611
Table 282: NIH’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1614
Table 283: NKT Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1618
Table 284: Non-industrial Sources’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1621
Table 285: Northwest Biotherapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1627
Table 286: Novartis’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1630
Table 287: OncoMed’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1638
Table 288: Oncothyreon’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1642
Table 289: Onyvax’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1646
Table 290: Oxford BioMedica’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1649
Table 291: Paladin Labs’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1652
Table 292: Panacea’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1658
Table 293: PanGenetics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1663
Table 294: Patrys’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1667
Table 295: Pepscan Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1672
Table 296: Peregrine Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1676
Table 297: Perseus Proteomics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1681
Table 298: Pfizer’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1684
Table 299: Philogen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1699
Table 300: Pierre Fabre’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1703
Table 301: Prima Biomed’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1711
Table 302: ProCell Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1714
Table 303: Prochon Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1717
Table 304: Progenics Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1721
Table 305: Ramot’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1724
Table 306: Recepta biopharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1727
Table 307: Receptor BioLogix’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1730
Table 308: Regeneron’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1734
Table 309: Sanofi-Aventis’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1741
Table 310: SBI Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1747
Table 311: Scancell’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1750
Table 312: Seattle Genetics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1753
Table 313: Shenogen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1760
Table 314: Stainwei Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1763
Table 315: Sunol Molecular’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1766
Table 316: SuppreMol’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1769
Table 317: Switch Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1772
Table 318: Symphogen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1775
Table 319: Synageva BioPharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1780
Table 320: SynerGene Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1788
Table 321: Takeda’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1791
Table 322: Targa Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1794
Table 323: TeGenero’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1800
Table 324: Teva’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1803
Table 325: Therapure Biopharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1808
Table 326: ThromboGenics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1811
Table 327: Titan Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1816
Table 328: Tolerx’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1821
Table 329: Tracon Pharmaceuticals’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1825
Table 330: Transgene’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1828
Table 331: Trillium Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1831
Table 332: Trion Pharma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1834
Table 333: UCB’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1841
Table 334: United Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1846
Table 335: Vaccinex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1849
Table 336: VasGene Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1857
Table 337: Viragen’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1860
Table 338: Viventia Biotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1864
Table 339: Wakunaga’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1867
Table 340: Wilex’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1871
Table 341: XBiotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1874
Table 342: Xencor’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1878
Table 343: Xerion’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1893
Table 344: Xoma’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1898
Table 345: Y’s Therapeutics’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1902
Table 346: YM BioSciences’ Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1906
Table 347: Zenotech’s Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1911

This report includes 196 companies plus their collaborators:
A&G Pharmaceutical
Abbott
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Affibody
Affimed Therapeutics
Affitech
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Alfacell
Algeta
ALSP
Altor BioScience
Amgen
Amorfix Life Sciences
Antisoma
Aphios
Apricus Biosciences
Arana Therapeutics
Arca biopharma
arGEN-X
Astellas
AstraZeneca
Avaxia
AVEO
Bayer
Berkeley Lab
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
Biosceptre
Biotecnol
Biotest
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Cancer Innovations
Cancer Research Technology
Celldex Therapeutics
Celltrion
Celtic Pharma
Center of Molecular Immunology
CG Therapeutics
Circadian Technologies
CSL
CuraGen
CureTech
CytImmune Sciences
Daiichi Sankyo
Dendreon
DiaMedica
Dompe
Dr Reddy’s
Dyax
Eisai
Elan
Eli Lilly
Emergent BioSolutions
Epitomics
EUSA Pharma
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galaxy Biotech
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Gilead Sciences
GlaxoSmithKline
Gliknik
Glycotope
Green Cross
Hawthorn Pharmaceuticals
Hoffmann-La Roche
Human Genome Sciences
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
Immutep
Innate Pharma
InNexus Biotechnology
Intracel
ISA Pharmaceuticals
ISU ABXIS
Johnson & Johnson
Kaketsuken
KaloBios
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
LFB Biotechnologies
LG Life Sciences
MacroGenics
MAT Biopharma
Medarex
MediGene
MedImmune
Menarini
Merck & Co
Merck KGaA
Merrimack
Micromet
Mitsubishi Tanabe Pharma
Mycenax
Neovacs
Neuren
NIH
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
OncoMed
Oncothyreon
Onyvax
Oxford BioMedica
Paladin Labs
Panacea
PanGenetics
Patrys
Pepscan Therapeutics
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
Philogen
Pierre Fabre
Prima Biomed
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
Ramot
Recepta biopharma
Receptor BioLogix
Regeneron
Sanofi-Aventis
SBI Biotech
Scancell
Seattle Genetics
Shenogen
Stainwei Biotech
Sunol Molecular
SuppreMol
Switch Pharma
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Takeda
Targa Therapeutics
TeGenero
Teva
Therapure Biopharma
ThromboGenics
Titan Pharmaceuticals
Tolerx
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
United Therapeutics
Vaccinex
VasGene Therapeutics
Viragen
Viventia Biotech
Wakunaga
Wilex
XBiotech
Xencor
Xerion
Xoma
YM BioSciences
Y’s Therapeutics
Zenotech
This report includes 531 antibody drugs in cancer. From Ceased to Marketed. Some examples are:
131I-tositumomab
abagovomab
aflibercept
alemtuzumab
AMG-386
bevacizumab
brentuximab vedotin
catumaxomab
cetuximab
denosumab
farletuzumab
galiximab
gemtuzumab ozogamicin
girentuximab
ibritumomab tiuxetan
inotuzumab ozogamicin
ipilimumab
lumiliximab
naptumomab estafenatox
necitumumab
nimotuzumab
obinutuzumab
ofatumumab
oregovomab
panitumumab
pertuzumab
ramucirumab
Reditux
rituximab
trastuzumab
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others.
    To find out more about The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant. Learn More


A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma. Learn More

Other selected research from the 'Oncology' category:


Leukemia Drug Pathway Analyzer
There are today at least 620 targeted molecular therapies known to affect more than 248 specific intracellular signaling pathways for the treatment of leukemia. The rational for this plethora of treatment strategies is based on our increasing understanding of the 309 drug targets that are included in this drug-pathway analyzing tool. No less than 300 of these have been recorded with mutations and 73 drug targets have mutations which have been causally implicated in cancer. Learn More


Breast Cancer Drug Pipeline Update
BioSeeker Group have identified 636 companies plus partners who are today developing 706 drugs targeting breast cancer in development. across 469 different targets. In addition, there are 7 suspended drugs and another 242 drugs where development has been ceased. Learn More

Other selected research from the 'Biologicals' category:


Antibodies in Oncology: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of antibodies in oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More


Biologicals in Oncology Drug Pipeline Update
BioSeeker Group have identified 1371 companies plus partners who are today developing 2823 biological drugs in 6088 developmental projects in cancer across 801 different targets. In addition, there are 25 suspended drugs and another 1050 drugs where development has been ceased. Learn More